Literature DB >> 20127527

Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome.

Takamasa Nishiuchi, Yuichi Okutani, Toshikazu Fujita, Kazuya Yoshida, Hiroaki Ohnishi, Reiji Haba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20127527     DOI： 10.1007/s12185-010-0500-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  13 in total

Review 1.  Polycythemia vera: myths, mechanisms, and management.

Authors:  Jerry L Spivak
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

2.  Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells.

Authors:  G J Kontoghiorghes; A May
Journal:  Biol Met       Date:  1990

3.  Early deferasirox treatment in a patient with myelodysplastic syndrome results in a long-term reduction in transfusion requirements.

Authors:  Silvana Capalbo; Giuseppina Spinosa; Maria Grazia Franzese; Gaetano Palumbo
Journal:  Acta Haematol       Date:  2009-03-16       Impact factor: 2.195

4.  The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload.

Authors:  P D Jensen; L Heickendorff; B Pedersen; K Bendix-Hansen; F T Jensen; T Christensen; A M Boesen; J Ellegaard
Journal:  Br J Haematol       Date:  1996-08       Impact factor: 6.998

5.  Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?

Authors:  A Cortelezzi; C Cattaneo; S Cristiani; L Duca; B Sarina; G L Deliliers; G Fiorelli; M D Cappellini
Journal:  Hematol J       Date:  2000

6.  Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes.

Authors:  Ramin Tehranchi; Rosangela Invernizzi; Alf Grandien; Boris Zhivotovsky; Bengt Fadeel; Ann-Mari Forsblom; Erica Travaglino; Jan Samuelsson; Robert Hast; Lars Nilsson; Mario Cazzola; Rolf Wibom; Eva Hellström-Lindberg
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

7.  Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.

Authors:  E Messa; D Cilloni; F Messa; F Arruga; A Roetto; G Saglio
Journal:  Acta Haematol       Date:  2008-10-01       Impact factor: 2.195

8.  Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.

Authors:  Masaaki Takatoku; Takashi Uchiyama; Shinichiro Okamoto; Yuzuru Kanakura; Kenichi Sawada; Masao Tomonaga; Shinji Nakao; Tatsutoshi Nakahata; Mine Harada; Takashi Murate; Keiya Ozawa
Journal:  Eur J Haematol       Date:  2007-03-28       Impact factor: 2.997

Review 9.  Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia.

Authors:  G Vreugdenhil; M Smeets; R A Feelders; H G van Eijk
Journal:  Acta Haematol       Date:  1993       Impact factor: 2.195

10.  A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.

Authors:  Keisuke Miyazawa; Kazuma Ohyashiki; Akio Urabe; Tomoko Hata; Shinji Nakao; Keiya Ozawa; Takayuki Ishikawa; Junji Kato; Yoichi Tatsumi; Hiraku Mori; Midori Kondo; Junsuke Taniguchi; Hiromi Tanii; Lisa Rojkjaer; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2008-07-04       Impact factor: 2.319
View more
  6 in total

1.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

2.  Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Authors:  Rebecca L C Adams; Robert J Bird
Journal:  Ther Adv Hematol       Date:  2013-04

Review 3.  Myelodysplastic Syndromes and Iron Chelation Therapy.

Authors:  Emanuele Angelucci; Silvana Anna Maria Urru; Federica Pilo; Alberto Piperno
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-03-01       Impact factor: 2.576

4.  Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.

Authors:  Tiziana Tataranni; Carmela Mazzoccoli; Francesca Agriesti; Luciana De Luca; Ilaria Laurenzana; Vittorio Simeon; Vitalba Ruggieri; Consiglia Pacelli; Gerardo Della Sala; Pellegrino Musto; Nazzareno Capitanio; Claudia Piccoli
Journal:  Stem Cell Res Ther       Date:  2019-06-13       Impact factor: 6.832

5.  Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis.

Authors:  Fanqiao Meng; Xiuqiong Chen; Shunjie Yu; Xiaotong Ren; Zhaoyun Liu; Rong Fu; Lijuan Li
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

6.  Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Authors:  Harpreet Kochhar; Chantal S Leger; Heather A Leitch
Journal:  Case Rep Hematol       Date:  2015-03-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.